| ²é¿´: 1817 | »Ø¸´: 3 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
zhuimenglxÒø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÖúÒ½Ò©·½ÃæµÄÂÛÎÄÕªÒªµÄ·Ò룬ӢÒ뺺£¬·Ç³£¸Ðл£¡
|
||
|
Subclinical Hyperthyroidism and the Risk of Coronary Heart Disease and Mortality Background Data from prospective cohort studies regarding the association between subclinical hyperthyroidism and cardiovascular outcomes are conflicting. We aimed to assess the risks of total and coronary heart disease (CHD) mortality, CHD events, and atrial fibrillation (AF) associated with endogenous subclinical hyperthyroidism among all available large prospective cohorts. Methods Individual data on 52 674 participants were pooled from 10 cohorts. Coronary heart disease events were analyzed in 22 437 participants from 6 cohorts with available data, and incident AF was analyzed in 8711 participants from 5 cohorts. Euthyroidism was defined as thyrotropin level between 0.45 and 4.49 mIU/L and endogenous subclinical hyperthyroidism as thyrotropin level lower than 0.45 mIU/L with normal free thyroxine levels, after excluding those receiving thyroid-altering medications. Results Of 52 674 participants, 2188 (4.2%) had subclinical hyperthyroidism. During follow-up, 8527 participants died (including 1896 from CHD), 3653 of 22 437 had CHD events, and 785 of 8711 developed AF. In age- and sex-adjusted analyses, subclinical hyperthyroidism was associated with increased total mortality (hazard ratio [HR], 1.24, 95% CI, 1.06-1.46), CHD mortality (HR, 1.29, 95% CI, 1.02-1.62), CHD events (HR, 1.21; 95% CI, 0.99-1.46), and AF (HR, 1.68; 95% CI, 1.16-2.43). Risks did not differ significantly by age, sex, or preexisting cardiovascular disease and were similar after further adjustment for cardiovascular risk factors, with attributable risk of 14.5% for total mortality to 41.5% for AF in those with subclinical hyperthyroidism. Risks for CHD mortality and AF (but not other outcomes) were higher for thyrotropin level lower than 0.10 compared with thyrotropin level between 0.10 and 0.44 mIU/L (for both, P value for trend, .03). Conclusions Endogenous subclinical hyperthyroidism is associated with increased risks of total, CHD mortality, and incident AF, with highest risks of CHD mortality and AF when thyrotropin level is lower than 0.10 mIU/L. |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
¾«Æ··Ò뼯½õ |
» ²ÂÄãϲ»¶
282Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
±¾¿Æ211ÉúÎïҽѧ¹¤³Ì085409Çóµ÷¼Á339·Ö
ÒѾÓÐ8È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ3È˻ظ´
284Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
385·Ö ÉúÎïѧ£¨071000£©Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
²ÄÁÏר˶ µ÷¼Á
ÒѾÓÐ14È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
306·Ö²ÄÁÏÓ뻯¹¤Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸211ÉúÎïѧ280·Ö Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
086000ÉúÎïÓëÒ½Ò©298µ÷¼ÁÇóÖú
ÒѾÓÐ9È˻ظ´
Ƶ»Øíííù
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 110
- Ó¦Öú: 13 (СѧÉú)
- ¹ó±ö: 0.566
- ½ð±Ò: 17171.4
- É¢½ð: 1586
- ºì»¨: 30
- ɳ·¢: 3
- Ìû×Ó: 3338
- ÔÚÏß: 545.1Сʱ
- ³æºÅ: 1238300
- ×¢²á: 2011-03-19
- ÐÔ±ð: GG
- רҵ: ½ðÊôÓлú»¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+2 2012-04-29 08:07:58
°®ÓëÓêÏÂ: , »¶Ó³£À´~£¡ 2012-04-29 08:08:11
zhuimenglx: ½ð±Ò+10, ¡ïÓаïÖú, лл£¡ 2012-05-01 15:23:13
°®ÓëÓêÏÂ: ½ð±Ò+2 2012-04-29 08:07:58
°®ÓëÓêÏÂ: , »¶Ó³£À´~£¡ 2012-04-29 08:08:11
zhuimenglx: ½ð±Ò+10, ¡ïÓаïÖú, лл£¡ 2012-05-01 15:23:13
|
´ÓһȺÈ˵ÃÑÇÁÙ´²¸ÐȾºÍ¹ÚÐIJ¡µÄÇé¿ö£¬ÎÒÃǵóöÁËÕâÑùÒ»¸ö½áÂÛÑÇÁÙ´²¸ÐȾÓë¹ÚÐIJ¡ÊÇÏ໥µÖÖÆµÄ¡£ÎÒÃÇÏëÒªµÃ³ö¹ÚÐIJ¡µÄËÀÍöÂÊ¡£¹ÚÐIJ¡µÄ·¢²¡ÊÇÄÚÉúµÄ¡£ÎÒÃǶÔ52674λ²ÎÓëÕß×÷¹ÚÐIJ¡µÄµ÷²é£¬ÆäÖÐÖ»ÓÐÊ®Ãû²¡Àý¡£´Ó22437λµ÷²éÕßÖÐÎÒÃÇ·¢ÏÖÁË6Ãû¹ÚÐIJ¡»¼Õߣ¬Í¬Ê±¶Ô8711λ²ÎÓëÕß½øÐÐÁËAFµÄ·ÖÎö¡£¼××´ÏÙ»úÄÜÕý³£Òâζ×ÅÖÎÁÆË®Æ½ÔÚ0.45µ½4.49mIU/L µÄ·¶Î§ÄÚ£¬Í¬Ê±ÄÚÉúÑÇÁÙ´²¸ÐȾµÄÖÎÁÆË®Æ½ÔÚ0.45 0.45 mIU/L £¬¼´Î¬³ÖÔÚÕý³£µÄÖÎÁÆË®Æ½ÄÚ¡£ ÎÒÃǶÔ52674λ²ÎÓëÕß½øÐзÖÎö£¬ÆäÖÐÓÐ2188£¨4.2%£©Î».´æÔÚÑÇÁÙ´²¸ÐȾ¡£¹²ÓÐ8527λ²ÎÓëÕß×îÖÕËÀÍö£¬3653λ²ÎÓëÕ߻ᷢÉúCHD¡£´ÓÄêÁäºÍÐÔ±ð·ÖÎö£¬ÑÇÁÙ´²¸ÐȾ(hazard ratio [HR], 1.24, 95% CI, 1.06-1.46)µÄ×ÜËÀÍöÂÊÔö¼Ó£¬CHD(HR, 1.29, 95% CI, 1.02-1.62)ËÀÍö£¬AFÇé¿öΪ(HR, 1.68; 95% CI, 1.16-2.43)£¬ÕâЩÓëÄêÁäºÍÐÔ±ðµÄ¹ØÏµ²»´ó¡£»òÕßDZÔڵĹÚÐIJ¡Óë½øÒ»²½µÄ¹ÚÐIJ¡·¢²¡ÒòËØÓйء£ÔÚÈ«²¿ËÀÍöÖÐÓÐ14.5%ÊÇËÀÓÚ¹ÚÐIJ¡¡£ ÓëÕý³£ÖÎÁÆË®Æ½Ïà±ÈCHDËÀÍöÖÎÁÆË®Æ½¸ü¸ß¡£ ×ÜÖ®£¬CHD,AF¶¼»áÄÚÉúÑÇÁÙ´²¸ÐȾ£¬´ÓÃæÊ¹CHDºÍAFµÄÖÎÁÆË®Æ½½µµÍ¡£ |

2Â¥2012-04-28 18:38:53
µç·ÖÎö»¯Ñ§
½ð³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 13
- Ó¦Öú: 46 (СѧÉú)
- ½ð±Ò: 2369.7
- ºì»¨: 10
- Ìû×Ó: 639
- ÔÚÏß: 218.7Сʱ
- ³æºÅ: 1693775
- ×¢²á: 2012-03-15
- רҵ: µç»¯Ñ§·ÖÎö
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+2 2012-04-29 08:08:17
°®ÓëÓêÏÂ: , »¶Ó³£À´~£¡ 2012-04-29 08:08:25
°®ÓëÓêÏÂ: ½ð±Ò+2 2012-04-29 08:08:17
°®ÓëÓêÏÂ: , »¶Ó³£À´~£¡ 2012-04-29 08:08:25
|
ÑÇÁÙ´²¼××´ÏÙ¹¦ÄÜ¿º½øÖ¢ºÍ¹ÚÐIJ¡µÄ·çÏÕ¼°ÆäËÀÍöÂÊ Ô¤ÆÚÈËȺÖÐÑо¿µÃµ½µÄ¹ØÓÚÑÇÁÙ´²¼××´ÏÙ¹¦ÄÜ¿º½øÖ¢ºÍÐÄѪ¹Ü³É¹ûÖ®¼äµÄ¹ØÁªµÄ±³¾°×ÊÁÏÊÇÏ໥ì¶ÜµÄ¡£ÎÒÃǵÄÄ¿µÄÊÇÆÀ¹À×Ü·çÏÕÓë¹Ú×´¶¯ÂöÐÄÔ༲²¡£¨CHD£©µÄËÀÍöÂÊ£¬¹ÚÐIJ¡Ê¼þ£¬ÔÚËùÓпÉÄܽӴ¥µ½µÄÔ¤ÆÚµÄÒ»´óȺÈËÖУ¬·¿²ü£¨AF £©ÓëÄÚÔ´ÐÔÑÇÁÙ´²¼×¿ºÓйء£ ·½·¨£º »ã¼¯ÁËÀ´×Ô10¸ö¶ÓÎéµÄ52 674µÄ¸ö²ÎÓëÕßÈË×ÊÁÏ£¬¸ù¾Ý6¸ö¶ÓÎé22 437²Î¼ÓÕßÏÖÓеÄÊý¾Ý£¬¶Ô¹ÚÐIJ¡²¡Àý½øÐÐÁË·ÖÎö£»¶ÔÀ´×Ô5¸ö¶ÓµÄ8711¸ö²ÎÓëÕß½øÐÐÁË·¿²ü²¡ÀýµÄ·ÖÎö¡£¼××´ÏÙ¹¦ÄÜÕý³£±»¶¨ÒåΪ´Ù¼××´ÏÙ¼¤ËØË®Æ½´¦ÓÚ0.45ºÍ4.49 mIU / LÖ®¼ä¼°ÄÚÔ´ÐÔÑÇÁÙ´²¼×¿º´Ù¼××´ÏÙ¼¤ËØË®Æ½µÍÓÚ0.45 MIU / L£¬ÓÎÀë¼××´ÏÙËØË®Æ½Õý³££¬²»°üÀ¨ÄÇЩ½ÓÊܼ××´ÏٸıäµÄÒ©Îïºó¡£ |
3Â¥2012-04-28 18:42:52
xzx8066
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 29
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2623.7
- ºì»¨: 2
- Ìû×Ó: 434
- ÔÚÏß: 89.1Сʱ
- ³æºÅ: 1350357
- ×¢²á: 2011-07-19
- ÐÔ±ð: GG
- רҵ: ÄÔ¡¢¼¹Ëè¡¢ÖÜΧÉñ¾ËðÉ˼°
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ...
zhuimenglx: ½ð±Ò+90, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, лл£¡ 2012-05-01 15:22:51
zhuimenglx: ½ð±Ò+90, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, лл£¡ 2012-05-01 15:22:51
|
ÑÇÁÙ´²¼××´ÏÙ¹¦ÄÜ¿º½ø£¨ÑÇÁÙ´²¼×¿º£©Ó뻼Õß¹ÚÐIJ¡ºÍËÀÍö·çÏÕ ±³¾°£º³¤ÆÚÒÔÀ´£¬Ñо¿ÕßÒ»Ö±»³ÒÉÑÇÁÙ´²¼×¿ºÓëÐÄѪ¹Ü¼²²¡Ô¤ºóÖ®¼ä´æÔÚ¹ØÁª£¬µ«ÊÇǰհÐÔ¶ÓÁÐÑо¿µÃ³öµÄ½áÂÛÏ໥ì¶Ü¡£±¾Ñо¿Ö¼ÔÚÜöÝÍ·ÖÎö´óÑù±¾Ç°Õ°ÐÔ¶ÓÁÐÑо¿ÖÐÊý¾ÝÀ´ÆÀ¼ÛÄÚÔ´ÐÔÑÇÁÙ´²¼×¿ºÊÇ·ñÔö¼ÓÈ«ÒòËÀÍö¡¢¹ÚÐIJ¡ËÀÍö¡¢¹ÚÐIJ¡Ê¼þºÍ·¿²ü·çÏÕ¡£ ·½·¨£º±¾Ñо¿Í¨¹ýÎÄÏ×¼ìË÷ÄÉÈë10¸öǰհÐÔ¶ÓÁÐÑо¿£¬¹²°üÀ¨52674Àý»¼Õߣ»ÆäÖÐ6¸ö¶ÓÁÐÑо¿ÖÐ22437Àý»¼Õß½øÐйÚÐIJ¡Ê¼þ·ÖÎö£¬5¸ö¶ÓÁÐÑо¿ÖÐ8711Àý»¼Õß½øÐйÂÁ¢ÐÔ·¿²ü½øÐзÖÎö¡£´Ù¼××´ÏÙ¼¤ËØË®Æ½Îª0.45~4.49 mIU/LÊÓΪ¼××´ÏÙ¹¦ÄÜÕý³££»Èç¹ûÆäˮƽµÍÓÚ0.45~4.49 mIU/L£¬¶ø¼××´ÏÙËØÕý³££¬²¢Åųý½ÓÊܸıä¼××´ÏÙ¹¦ÄÜÒ©ÎïÕߣ¬Ôò³ÆÎªÑÇÁÙ´²¼×¿º¡£ ½á¹û£º52674Àý»¼ÕßÖУ¬2188Àý·¢ÉúÑÇÁÙ´²¼×¿º£¬·¢ÉúÂÊΪ4.2%¡£Ëæ·ÃÆÚ¼ä£¬8527Àý»¼ÕßËÀÍö£¨ÆäÖÐ1896ÀýËÀÓÚ¹ÚÐIJ¡£©£¬3653Àý·¢Éú¹ÚÐIJ¡Ê¼þ£¬785Àý·¢Éúż·¢ÐÔ·¿²ü¡£½øÐÐÄêÁäºÍÐÔ±ð½ÃÕýºó·ÖÎö·¢ÏÖ£¬Ïà¶ÔÓÚ¼××´ÏÙ¹¦ÄÜÕý³£µÄ¶ÔÕÕ»¼Õߣ¬ÑÇÁÙ´²¼×¿º»¼ÕßÈ«ÒòËÀÍö×ÜΣÏձȣ¨HR£©Îª1.24£¨95%¿ÉÐÅÇø¼äΪ1.06~1.46£©¡¢¹ÚÐIJ¡ËÀÍöHRΪ1.29£¨95%¿ÉÐÅÇø¼äΪ1.02~1.62£©¡¢¹ÚÐIJ¡Ê¼þHRΪ1.21£¨95%¿ÉÐÅÇø¼äΪ0.99~1.46£©£¬Å¼·¢ÐÔ·¿²üHRΪ1.68£¨95%¿ÉÐÅÇø¼äΪ1.16~2.43£©£¬¶øÄêÁä¡¢ÐÔ±ð¡¢ÐÄѪ¹Ü¼²²¡Ê·¶ÔHRÎÞÓ°Ïì¡£ÀàËÆµØ£¬½øÐÐÐÄѪ¹ÜΣÏÕÒòËØ½ÃÕýºó£¬·¿²ü¶ÔÈ«ÒòËÀÍöµÄ¹éÒòΣÏÕ¶ÈÓÉ14.5%Ôö¼Óµ½41.5%¡£ÑÇÁÙ´²¼×¿º»¼ÕßÖУ¬´Ù¼××´ÏÙ¼¤ËØË®Æ½µÍÓÚ0.10 mg/LÕßÓë´Ù¼××´ÏÙ¼¤ËØË®Æ½½éÓÚ0.10~0.44 mg/LÖ®¼äÕßÏà±È£¬¹ÚÐIJ¡ËÀÍöºÍ·¿²ü·çÏÕÔö¸ß£¨Á½Õß¾ùP<0.03£©¡£ ½áÂÛ£ºÄÚÔ´ÐÔÑÇÁÙ´²¼×¿º¿ÉÔö¼Ó¹ÚÐIJ¡ËÀÍö¡¢È«ÒòËÀÍöºÍ·¿²ü·çÏÕ¡£µ±´Ù¼××´ÏÙËØË®Æ½µÍÓÚ0.10 mIU/Lʱ£¬¹ÚÐIJ¡ËÀÍöºÍ·¿²ü·çÏÕÔö¸ß×îΪÏÔÖø¡£ |
4Â¥2012-04-29 11:22:01














»Ø¸´´ËÂ¥
120